New combo therapy hopes to boost immune attack on rare skin cancer
NCT ID NCT05838599
First seen May 03, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tests whether adding a topical immune-stimulating cream (imiquimod) to standard local radiation therapy can improve treatment of mycosis fungoides, a rare skin lymphoma. About 25 adults with early-stage disease who have not responded to at least one prior therapy will receive the cream for a week before radiation to prime the immune system. The main goals are to check safety and measure skin disease response at 8 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University Department of Dermatology
RECRUITINGChicago, Illinois, 60611, United States
Contact
Conditions
Explore the condition pages connected to this study.